Dostinex is a prescription medication marketed in Hong Kong that contains cabergoline as its active ingredient. Cabergoline belongs to the class of dopamine-agonist drugs and is formulated as oral pill tablets that are available in 0.25 mg and 0.5 mg strengths. In Hong Kong the product is regulated by the Department of Health and is supplied only with a medical prescription. While the brand name Dostinex is most widely recognized, the same active ingredient can be found in other generic formulations.
Cabergoline is a long-acting dopamine D₂ receptor agonist. By stimulating these receptors in the pituitary gland, it suppresses the secretion of prolactin, a hormone that influences menstrual cycles, lactation, and reproductive health.
Because of its high affinity and long half-life (≈ 65 hours), cabergoline can be dosed only a few times per week while maintaining steady hormone control.
Dostinex is approved in Hong Kong for the following women’s-health indications:
These approvals are based on robust clinical trials that demonstrated rapid prolactin normalisation and tumor size reduction in the majority of patients. Dostinex is typically prescribed to women experiencing menstrual irregularities, infertility, or galactorrhoea linked to excess prolactin.
Research outside the approved label has explored cabergoline for several additional purposes. Where evidence is present, it is highlighted with the required disclaimer.
Disclaimer: Off-label use of Dostinex requires close medical supervision and a personalised risk-benefit assessment.
If any of the above conditions apply, a healthcare professional should evaluate the suitability of Dostinex on an individual basis.
These reactions are usually mild and improve with continued therapy or dose adjustment.
If any of the serious symptoms appear, seek medical attention promptly.
Patients should provide a complete medication list, including over-the-counter drugs, supplements, and herbal products, before starting Dostinex.
| Strength | Typical Starting Dose | Maintenance Dose | Maximum Recommended | |-|-||| | 0.25 mg | 0.25 mg twice weekly (e.g., Monday & Thursday) | 0.5 mg twice weekly | 1 mg twice weekly |
If a dose is missed, take it as soon as remembered provided it is at least 12 hours before the next scheduled dose. Do not double the dose to make up for a missed tablet.
Symptoms may include severe nausea, vomiting, profound hypotension, and hallucinations. Seek emergency medical care immediately; supportive measures and monitoring are the mainstays of treatment.
Abrupt stopping is generally safe, but clinicians may choose a gradual taper if the medication has been used at higher doses for an extended period, to minimise rebound hyperprolactinemia.
Regular follow-up visits allow dose optimisation, early detection of side effects, and assessment of tumor size via imaging when indicated.
This article provides educational information about Dostinex (cabergoline) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Cabergoline can suppress lactation, and some clinicians prescribe it for this purpose, but it is not an FDA- or Hong Kong-approved indication. Use should be discussed with a specialist to weigh benefits against potential side effects.
Most patients experience a measurable reduction in serum prolactin within 2-3 days, though full normalisation may take several weeks of therapy.
Yes, provided the medication is kept in its original packaging with the prescription label. Carry a copy of the prescription and be aware of any import restrictions for controlled substances in the destination country.
Sit or lie down immediately, hydrate, and rise slowly from a seated position. If the symptom persists or is severe, contact your healthcare provider, as dosage adjustment may be required.
There is no known pharmacokinetic interaction between cabergoline and combined oral contraceptives. However, discuss all medications with your prescriber to ensure coordinated care.
Cabergoline stimulates dopamine receptors in the gut, which can trigger nausea. Taking the tablet with a small meal or snack often reduces this effect.
No specific foods must be avoided, but excessive alcohol may increase dizziness. Maintaining a balanced diet supports overall health while on therapy.
Both are dopamine agonists; cabergoline generally requires fewer weekly doses due to its longer half-life and may be better tolerated. Choice of agent depends on individual response and physician preference.
Cabergoline does not directly influence thyroid hormone production, but prolactin-related pituitary abnormalities can occasionally affect surrounding hormone axes. Routine thyroid testing is not mandated solely because of Dostinex therapy.
Pricing varies by pharmacy and insurance coverage. Generic versions are typically less expensive, but exact costs should be obtained from local dispensaries.
